BioSight
BioSight37About
What does BioSight do?
BioSight is a private, clinical-stage biotechnology company focused on developing innovative therapeutics for hematological malignancies and disorders. Their lead product, BST-236 (aspacytarabine), is a proprietary anti-metabolite designed to address unmet medical needs by enabling high-dose chemotherapy.
What is BioSight's revenue?
StartupHub estimates BioSight's annual revenue at $500K (range $286K to $800K, 64% confidence), based on comparable companies in the sector.
What is BioSight's valuation?
StartupHub estimates BioSight's effective valuation at $5.6M (range $3.8M to $9.0M, 10% confidence), based on comparable companies in the sector.
How much funding has BioSight raised?
BioSight has raised a total of $2M in funding.
Where is BioSight headquartered?
BioSight is headquartered in Tel Aviv, Israel.
When was BioSight founded?
BioSight was founded in 1999.
What industry does BioSight operate in?
BioSight operates in Life Sciences, Biotech, MedTech, HealthTech, Clinical Trials, Drug Discovery.
How many employees does BioSight have?
BioSight has approximately 3 people on record.
No comments yet. Be the first to share your take.